Navigation Links
Heska Announces Q309 Results

LOVELAND, Colo., Oct. 27 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA; "Heska" or the "Company") today reported financial results for its third quarter ended September 30, 2009.


"The third quarter of 2009 was the most profitable quarter this year and the financial performance exceeded our latest guidance. The strong cash flow from our operations has allowed us to reduce our borrowings significantly," said Robert Grieve, Heska's Chairman and CEO. "We are excited by our future prospects, including the market opportunity presented by the DRI-CHEM 7000® Veterinary Chemistry Analyzer - a new, high-end chemistry instrument that is a line-extension to our current offering."

Investor Conference Call

Management will conduct a conference call on Tuesday, October 27, 2009 at 9:00 a.m. MDT (11:00 a.m. EDT) to discuss the third quarter 2009 financial results. To participate, dial (877) 941-8609 (domestic) or (480) 629-9818 (international); the conference call access number is 4171626. The conference call will also be broadcast live over the Internet at To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback until November 10, 2009. The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international). The webcast replay may be accessed from Heska's home page at until November 10, 2009.

About Heska

Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the anticipated loss, after November 1, 2009, of access to products from Abbott Point of Care Inc., which represent approximately 18% of Heska's revenue for the year ended September 30, 2009, as well as uncertainties related to the loss of exclusive access to these products on May 1, 2009; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; uncertainties surrounding the success of future products, including Heska's ability to adhere to stated deadlines and successfully commercialize such products; risks regarding Heska's ability to successfully market, sell and distribute its products in an economically sustainable manner; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose exclusive rights or access to a product due to a supplier decision or for other reasons; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; uncertainties regarding Heska's ability to continue to meet its covenant obligations under its borrowing agreement; uncertainties related to Heska's ability to raise additional capital, if necessary or advisable; the level of Heska's fixed expense, which is significant, and the corresponding cash flow and liquidity-related risks resulting from unanticipated revenue and gross margin shortfalls; uncertainties regarding overall economic conditions, the affect of these conditions on Heska's business, which may change as compared to historical results, and Heska's accuracy in predicting these and related matters; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2009.

                             Financial Table Follows:

                      Consolidated Statements of Operations
                     In Thousands, Except per Share Amounts

                               Three Months Ended     Nine Months Ended
                                  September 30,         September 30,
                               -------------------    -----------------
                               2008         2009      2008        2009
                               ----         ----      ----        ----
    Revenue, net:
        Core companion
         animal health       $19,240      $16,892   $54,473     $51,908
        Other vaccines,
         and products          2,446        2,658    11,746       6,412
                               -----        -----    ------       -----
          Total revenue, net  21,686       19,550    66,219      58,320
                              ------       ------    ------      ------

    Cost of revenue           13,490       12,130    41,716      36,496
                              ------       ------    ------      ------

    Gross profit               8,196        7,420    24,503      21,824
                               -----        -----    ------      ------

        Selling and
         marketing             4,458        3,695    14,024      11,075
        Research and
         development             506          457     1,462       1,308
        General and
         administrative        2,134        2,109     6,756       6,255
                               -----        -----     -----       -----
             Total operating
              expenses         7,098        6,261    22,242      18,638
                               -----        -----    ------      ------
    Operating income           1,098        1,159     2,261       3,186
    Interest and other
     (income) expense,
     net                         153          (13)      500         193
                                 ---          ---       ---         ---
    Income before
     income taxes                945        1,172     1,761       2,993
    Income tax expense           368          429       744       1,211
                                 ---          ---       ---       -----
    Net income                  $577         $743    $1,017      $1,782
                                ====         ====    ======      ======

    Basic net income
     per share                 $0.01        $0.01     $0.02       $0.03
                               =====        =====     =====       =====
    Diluted net income
     per share                 $0.01        $0.01     $0.02       $0.03
                               =====        =====     =====       =====

    Shares used for
     basic net income
     per share                51,797       52,123    51,625      52,049
                              ======       ======    ======      ======

    Shares used for
     diluted net
     income per share         52,580       52,192    53,774      52,060
                              ======       ======    ======      ======
                                Balance Sheet Data
                             In Thousands (unaudited)

                                             December 31,  September 30,
                                                 2008          2009
                                                 ----          ----
    Cash and cash equivalents                   $4,705        $5,603
    Total current assets                        31,290        29,530
    Total assets                                70,438        65,992
    Line of credit                              11,042         5,984
    Current portion of long-term debt              770           573
    Total current liabilities                   22,228        16,360
    Long-term debt, net of current
     portion                                       381             -
    Stockholders' equity                        42,523        44,637

SOURCE Heska Corporation

SOURCE Heska Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... has partnered with Mediaplanet to help educate the many who are unaware of ... section dedicated to aphasia will run within the “Stroke Awareness” campaign. , The ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... Award for its use of effective workplace strategies to increase business and employee success. ... the Families and Work Institute (FWI) and the Society for Human Resource Management (SHRM), ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in ... 5, 2016, communities around the world will gather to recognize these cancer survivors as ... Day® is an annual worldwide Celebration of Life that is held on the first ...
Breaking Medicine News(10 mins):